In another study, NF1 mutations were documented in BRAF-mutant tumor cells that were intrinsically resistant to BRAF inhibition, and in melanoma tumors from patients exhibiting resistance to vemurafenib, thus demonstrating the clinical significance for NF1-driven resistance to RAF/MEK-targeted therapies [87]. This evidence concerns the gene NF1 and neoplasm.